Core Viewpoint - The company has entered into an exclusive licensing agreement with Pfizer for the development, production, and commercialization of its breakthrough PD-1/VEGF bispecific antibody, SSGJ-707, outside of mainland China, while retaining rights for mainland China [1][2] Group 1: Licensing Agreement Details - The agreement includes an upfront payment of $1.25 billion and potential total payments of up to $4.8 billion, which are non-refundable and non-offsettable [1] - The company will receive a double-digit percentage royalty on net sales of the product in the licensed regions [1] Group 2: Product Development and Clinical Trials - SSGJ-707 is based on the proprietary CLF2 platform and is currently undergoing multiple clinical studies in China, including a Phase III trial for first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [2] - The product has received breakthrough therapy designation in China and is also involved in several Phase II studies for various cancers [2] Group 3: Share Subscription Agreement - Pfizer will subscribe to $100 million worth of ordinary shares based on the 30-day volume-weighted average price, with terms to be negotiated in a formal agreement following the licensing agreement [2]

（於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：01530） 內幕消息公告 (1)與輝瑞就PD-1/VEGF雙特異性抗體(SSGJ-707) 訂 立 許 可 協 議； 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 的 全 部 或 任 何 部 份 內 容 所 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 及 (2)輝瑞可能認購若干數目的本公司新股份 本公告由三生制药（「本公司」，連 同 其 附 屬 公 司，統 稱「本集團」）根據香港聯合交 易所有限公司證券上市規則（「上市規則」）第13.09(2)條及香港法例第571章證券及 期貨條例第XIVA部項下的內幕消息條文（定 義 見 上 市 規 則）作 出。 (1) 與輝瑞就PD-1/VEGF雙特異性抗體(SSGJ-707)訂立許可協議 許可協議 本公司董事會（「董事會」）欣 然 ...

公开信息显示，现任基金经理晏青先生:中国国籍,上海交通大学经济学硕士。曾任交银施罗德基金管理 有限公司研究员、基金经理,上海弘尚资产管理中心(有限合伙)投资经理、海外投资总监。现任永赢基金 管理有限公司权益投资部副总经理。2019年10月16日至2020年11年10月担任永赢创业板指数型发起式证 券投资基金的基金经理;2020年3月25日至2023年10月17日,担任永赢股息优选混合型证券投资基金的基 金经理。2020年9月29日至今,担任永赢港股通品质生活慧选混合型证券投资基金的基金经理。曾任永赢 股息优选混合型证券投资基金基金经理。2021年5月14日担任永赢港股通优质成长一年持有期混合型证 券投资基金的基金经理。 5月19日，永赢港股通优质成长一年混合（011315）下跌0.84%，最新净值0.72元，连续3个交易日下 跌，区间累计跌幅1.67%。 据了解，永赢港股通优质成长一年混合成立于2021年5月，基金规模2.40亿元，成立来累计收益 率-27.57%。从持有人结构来看，截至2024年末，永赢港股通优质成长一年混合的基金机构持有0.02亿 份，占总份额的0.58%，个人投资者持有3.40亿份，占总 ...

5月19日上榜港股通成交活跃榜个股中，三生制药为近一个月首次上榜。 证券时报·数据宝统计显示，5月19日港股通（包括沪市港股通及深市港股通）成交活跃股合计成交 378.81亿港元，占当日港股通成交金额的44.83%，净买入金额38.58亿港元。 上榜的成交活跃股中，阿里巴巴-W成交额为98.74亿港元，成交金额居首；其次是小米集团-W、腾讯控 股，成交金额分别为88.56亿港元、51.58亿港元。 以上榜次数统计，5月19日上榜个股中，近一个月上榜次数最多的是阿里巴巴-W、美团-W等，近一个 月均上榜17次，最受港股通资金关注。 三生制药为近一个月首次上榜，当日港股通成交额为18.13亿港元，成交净买入4.01亿港元，该股当日收 盘上涨13.81%。（数据宝） 5月19日港股通成交活跃股榜单 | 证券 | 证券简称 | 成交金额（亿 | 净买入金额（亿 | 近一个月上榜 | 最新收盘价 | 日涨跌幅 | | --- | --- | --- | --- | --- | --- | --- | | 代码 | | 港元） | 港元） | 次数 | （港元） | （%） | | 00700 | 腾讯控股 | 51.5 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The development of trispecific antibodies (TsAbs) is accelerating, with a focus on companies such as Zai Lab and Sanofi [18]. - The report highlights the performance of various sub-sectors within the industry, ranking them as follows: innovative drugs > CXO > traditional Chinese medicine > medical devices > pharmacies > pharmaceutical commerce [12][13]. Summary by Sections Industry Performance - The A-share pharmaceutical index has increased by 1.3% this week and 2.5% year-to-date, outperforming the CSI 300 by 0.2% and 3.6% respectively [11]. - The H-share biotechnology index has shown a 0.3% increase this week and a 27.8% increase year-to-date, outperforming the Hang Seng Technology Index by -1.7% and 9.6% respectively [11]. Specific Company Recommendations - From a growth perspective, the report recommends focusing on innovative drug companies such as Zai Lab, Sanofi, and others [13]. - For undervalued stocks, it suggests looking into traditional Chinese medicine companies like Zai Lab and Dong-E E-Jiao [13]. - High dividend yield stocks are recommended from the traditional Chinese medicine sector, including Jiangzhong Pharmaceutical and Yunnan Baiyao [13]. Trispecific Antibodies Development - TsAbs are engineered antibodies capable of binding to three different antigen targets, offering enhanced therapeutic potential in cancer immunotherapy [18]. - Currently, no TsAbs have been approved for market, but several companies, including Zai Lab and Sanofi, are actively developing these therapies [18][32]. Clinical Progress - The report outlines the clinical stages of various TsAbs, noting that Zai Lab's ZG006 is among the leading candidates in clinical trials [32]. - Other notable candidates include those from companies like Sanofi and IBI3003 from Innovent Biologics, which are also in advanced clinical stages [32].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The development of trispecific antibodies (TsAbs) is accelerating, with a focus on companies such as Zai Lab and Sanofi [18]. - The report highlights the performance of various sub-sectors within the industry, ranking them as follows: innovative drugs > CXO > traditional Chinese medicine > medical devices > pharmacies > pharmaceutical commerce [12][13]. - Specific stock selection strategies are recommended based on growth potential, valuation, dividend yield, and left-side investment opportunities [13]. Summary by Sections Industry Performance - The A-share pharmaceutical index has increased by 1.3% this week and 2.5% year-to-date, outperforming the CSI 300 by 0.2% and 3.6% respectively [11]. - The H-share biotechnology index has shown a 0.3% increase this week and a 27.8% increase year-to-date, outperforming the Hang Seng Technology Index by -1.7% and 9.6% respectively [11]. Trispecific Antibodies - TsAbs are engineered antibodies capable of binding to three different antigen targets, offering enhanced therapeutic potential in cancer immunotherapy [18]. - Currently, no TsAbs have been approved for market, but several companies, including Zai Lab and Sanofi, are actively developing these therapies [18][32]. Stock Recommendations - Growth-oriented stock picks focus on innovative drug companies such as Zai Lab, Sanofi, and others [13]. - For undervalued stocks, the report recommends traditional Chinese medicine companies like Zai Lab and Dong-E E-Jiao [13]. - High-dividend stocks are primarily found in the traditional Chinese medicine sector, with companies like Jiangzhong Pharmaceutical and Yunnan Baiyao highlighted [13]. Clinical Development - The report outlines the clinical stages of various trispecific antibody drugs, noting that the fastest progress is seen in Merck's Restoret, currently in phase 2b/3 trials [31]. - Domestic companies are also advancing in this area, with Zai Lab's ZG006 and others in clinical stages [32].

格隆汇5月16日｜港股药品股拉升明显，其中，山东新华制药一度大涨近16%表现抢眼，天大药业、德 琪医药涨超6%，三生制药、远大医药涨5.6%，石药集团、信达生物涨超2%。 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com | 代码 | 名称 | 最新价 | 涨跌幅 ▽ | | --- | --- | --- | --- | | 00719 | 山东新华制药股 | 6.260 | 9.82% | | 00932 | 顺腾国际控股 | 0.025 | 8.70% | | 00455 | 天大药业 | 0.152 | 6.29% | | 06996 | 德琪医药-B | 3.440 | 6.17% | | 01530 | 三生制药 | 12.100 | 5.77% | | 00512 | 远大医药 | 8.650 | 5.62% | | 00950 | 李氏大药厂 | 1.400 | 4.48% | | 0689 ...

Group 1 - The monitoring report from the Chinese CDC indicates an upward trend in the COVID-19 positive rate in April, with southern provinces showing higher rates than northern ones [1] - In Hong Kong, the COVID-19 positive rate increased from 1.71% to 8.21% over four weeks, indicating a rising trend in the region [1] - Taiwan reported a significant increase in emergency visits related to COVID-19, with a 66% rise in cases and additional severe cases and deaths [1] Group 2 - The Chinese CDC reported an increase in the COVID-19 positive rate among flu-like cases in emergency departments, rising from 7.5% to 16.2% [2] - Among hospitalized severe acute respiratory infection cases, the COVID-19 positive rate increased from 3.3% to 6.3% during the monitoring period [2] - The new coronavirus has surpassed rhinovirus as the leading cause of emergency visits for flu-like cases in the specified three-week period [2] Group 3 - Relevant pharmaceutical companies in the Hong Kong stock market include Shandong Xinhua Pharmaceutical (00719), Jinhongzi (06896), Sanofi (01530), and Dongyangguang Changjiang Pharmaceutical (01558) [3]

Group 1 - The Hang Seng Medical Index ETF has shown significant liquidity with a turnover of 1% and a transaction volume of 2.6148 million yuan, with an average daily transaction volume of 27.4616 million yuan over the past month [2] - The ETF's scale has increased by 28.6087 million yuan in the past month, ranking first among comparable funds, with a share increase of 12 million units in the last two weeks, also the highest among peers [2] - In terms of capital inflow, the ETF has seen net inflows on 5 out of the last 8 trading days, totaling 14.5271 million yuan [2] - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Healthcare Index is 23.4, which is in the 4.36% percentile over the past year, indicating a valuation lower than 95.64% of the time in the past year, suggesting historical low valuations [2] - The top ten weighted stocks in the Hang Seng Medical Healthcare Index account for 57.09% of the index, including companies like WuXi Biologics and BeiGene [2] Group 2 - Since the reform of new drug research and development policies in 2015, China's innovative drug industry has developed a strong ecosystem, integrating excellent resources in preclinical and clinical stages, which has gained recognition from multinational corporations (MNCs) [3] - The pharmaceutical and biotechnology sector's Q1 2025 financial reports show stable revenue and profit performance, with notable improvements in certain sub-industries, indicating a return of market enthusiasm for the sector [3] - There is a recommendation to focus on international biotech companies, revaluation of innovative pipelines in generic companies, and companies in the CXO industry with significant order and operational improvements [3] - Investors without stock accounts can access investment opportunities in the Hong Kong medical sector through the Hang Seng Medical Index ETF linked fund (018433) [3]

中邮证券表示，受益于海外投融资市场的率先复苏，需求端逐步恢复，CXO&上游公司订单增速提升， 行业拐点已过。CXO板块收入端恢复良好增长态势，盈利能力持续修复，利润端改善趋势更为显著， 基本面已呈现向上趋势。优质、高效、低成本的产品及服务为核心壁垒，我国制药业优势持续巩固，有 望在全球市场占据更高市场份额。中国创新药经过数十年发展，正在进入收获期，叠加政策友好性和市 场流动性提升，国内创新药市场前景光明。建议重点关注肿瘤、自免、减重、阿尔兹海默症、NASH、 脱发、乙肝等领域。 甬兴证券表示，百济神州凭借泽布替尼在欧美市场份额的提升保持收入规模的增长、恒瑞医药也多次实 现创新药的对外授权，我们认为国产创新药的竞争力正在持续提升，看好国产创新药的出海前景。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） 5月14日港股低开低走，医药生物板块逆市走强。热门ETF方面，港股创新药ETF（159567）盘中震荡 走高，截至发稿涨1.01%。换手率超7%，成交额快速突破1亿元，交投活跃。 成分股方面，三生制药涨超4%，康希诺生物、凯莱英涨超3%，晶泰控股、再鼎医药、科 ...